For nearly 20 years, Selexis has been helping its partners predictably, rapidly and cost-effectively generate life-saving biologic medicines and vaccines. Its SUREtechnology Platform™ is being used by clients worldwide, resulting in more than 119 biologic drug products in clinical and commercial manufacturing. Selexis is able to generate stable and high-expressing (2–7 g/L for MAbs, >1.5g/L for bispecific antibodies, fed batch in shake flask, >10 g/L in bioreactor) research cell banks (RCBs) in as little as 14 weeks.
April 13, 2019
Keywords: cell line development, clonal cell line, SUREtechnology, recombinant protein expression, research cell bank, clonal cell lines